CD276 and melanoma: Additionally, B7-H3 has been shown to reduce the efficacy of dacarbazine (DTIC) chemotherapy, along with small-molecule inhibitors targeting the MAP kinase (MAPK) and AKT/mTOR pathways in vitro; conversely, inhibition of B7-H3 enhanced the responsiveness of metastatic melanoma cells to these therapeutic agents [77].